Research programme: antibody-drug conjugates - Heidelberg Pharma/Nordic Nanovector

Drug Profile

Research programme: antibody-drug conjugates - Heidelberg Pharma/Nordic Nanovector

Alternative Names: NN-ATACs

Latest Information Update: 02 Nov 2016

Price : $50

At a glance

  • Originator Heidelberg Pharma; Nordic Nanovector
  • Class Antibodies; Antineoplastics; Drug conjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies

Most Recent Events

  • 26 Oct 2016 Early research in Haematological malignancies in Germany (unspecified route)
  • 26 Oct 2016 Early research in Haematological malignancies in Norway (unspecified route)
  • 26 Oct 2016 Nordic Nanovector and Heidelberg Pharma enter a research collaboration for antibody-drug conjugates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top